Wordt geladen...
Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens
Fosaprepitant dimeglumine (Emend IV(®)) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. Aprepitant (Emend(®)) is an oral medication that is administered for three consecutive days, whereas fosaprepitant is a single-dose IV medication that is administered...
Bewaard in:
| Gepubliceerd in: | Clin J Oncol Nurs |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510647/ https://ncbi.nlm.nih.gov/pubmed/27668376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1188/16.CJON.555-556 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|